Radius

Fineurop Soditic acted as exclusive financial advisor to the shareholders of Radius S.r.l. on the sale of control to Else Solutions, held by the fund 21 Invest Healthcare since October 2025.

Founded in Budrio (Bologna) by the Mei family, who will reinvest in the transaction, Radius is active in the distribution of systems and devices for nuclear medicine and radiotherapy.
In particular, Radius distributes highly innovative and technologically advanced products and is a reference point for the Italian scientific community in radiotherapy, nuclear medicine, and pre-clinical research, with a portfolio of products from leading international manufacturers.
Over the past three years, Radius has posted average annual growth of 40%, recording revenues of approximately Euro 17 million in 2025 and EBITDA of approximately Euro 3.2 million, up 60% on 2024.

The acquisition is part of a broader development path for Else Solutions, aimed at consolidating its leadership in distribution and driving growth in the radiopharmaceutical handling systems sector, where the company stands out for a highly competitive and cutting-edge product portfolio, supported by strengthened production capacity. At the same time, the company will continue its international expansion into high-potential markets, already under way during 2025.

Following the integration, Else Solutions will reach combined revenues of Euro 35 million, EBITDA of approximately Euro 7 million, and a workforce of approximately 70 employees, consolidating its growth trajectory and doubling in size in less than one year.